Allergan is acquiring Map Pharmaceuticals for $961 million or $25 per share in cash

Map Pharmaceuticals Inc.

U.S. / Small-Cap Biopharma (<$1 billion)

Seller

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Allergan Inc.

U.S. / Mid-Cap Biopharma ($1-$50 billion)

Buyer

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Completed

Sample

01/01/2009

announced

01/01/2009

completed